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Mincreased operative risk. The Cox Maze III may signifi-
cantly improve their outcome.
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Dr John Doty (Murray, Utah). This study represents a propen-
sity-based analysis of adding surgical ablation to AVR and coro-
nary bypass. These are procedures that typically do not require
an atriotomy like a mitral valve operation. This shows that adding
a concomitant modified CoxMaze operation will have similar out-
comes but does not increase mortality and supports the safety and
efficacy of AF ablation operations.
I have 3 areas I would like you to clarify. First, I would recom-
mend you use the terminology ‘‘modified Cox Maze III’’ because
I believe that you use both cryoablation and radiofrequency. Can
you explain the percentage of patients you used for each of those
and how your group selects which energy modality that you use?
Dr Ad. I disagree with you on the definition. It is not a modified
Cox Maze procedure. The Cox Maze procedure is a principle, and
the CoxMaze III procedure is a set of lesions that are being applied
as a template and it does not matter how you deliver the lesions.
The terminology of a modified Cox Maze procedure is confusing
because it does not matter how you perform the entire lesions of
the Cox Maze procedure, radiofrequency, cryotherapy, and so
on. It is a principle that we should all account for. The Cox
Maze III procedure is a concept. I disagree with the terminology
of modified, and I am clear about it whenever I give a talk on
the topic.
In this series, the patients had the Cox Maze procedure lesion
set. Basically, in the past we used a combined bipolar radiofre-
quency ablation and cryotherapy. On the basis of our observation
with bipolar radiofrequency ablations related to reconnections as
published in a few articles in the past few years, we moved away
from that. Currently, all of our patients are now are being treated
with cryothermal energy.
Dr Doty. Second, your midterm results for restoration of sinus
rhythm are excellent. How do you measure that, and has there been
a difference between the radiofrequency and cryoablation cases
over time?
Dr Ad. Basically there is no difference between the different
energy sources as of yet, but we still follow all the patients. We de-
veloped our own registry and a follow-up system that is based on 3,
6, 9, 12, 18, and 24 months, and yearly thereafter, and at each time
point the patients are measured with electrocardiogram and 24-
hour Holter monitoring. However, at 6 and 24 months they are
also getting a 1-week Holter monitor. The results reported in this
article are based only on electrocardiogram and Holter monitoringrdiovascular Surgery c Volume 143, Number 4 943
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Mbecause not all patients agree to wear a monitor for 1 week at 6 and
24 months. To just level the playing field, those reports are per
electrocardiogram and Holter monitoring, and Heart Rhythm So-
ciety guidelines are being used, meaning that any event more
than 30 seconds is a failure.
Dr Doty. Finally, as you mentioned, some surgeons are reluc-
tant to add an ablation procedure, even those with small incisions
using alternative energy because of the perceived risk of bleeding
and prolonged bypass. Could you elaborate on your series of pa-
tients and results with that, particularly among your own partners?
You mentioned that you do ablation in almost all of your patients,
but you are having different results from the rest of the group.
Dr Ad. I think that is one of the key points. True prospective
randomized studies looking at multiple centers are lacking. We
just submitted an abstract to the Society of Thoracic Surgeons
on a scoring system in which we score 1 and 0 using different vari-
ables, such as older age and EF, and then we factor in the surgeon
experience. What we found is that the percentage of patients in
whom the Maze procedure was performed is decreasing when
the surgeon experience is limited or the complexity of the case
is higher. This resulted in more patients directed to me, and now
I am performing approximately 90% to 95% of those procedures
for our group; it is the same process with other procedures when
you get into this subspecialization within the group. The real an-
swer should come with an effort looking into a prospective ran-
domized study, and I know there is such an effort through the
Cardiothoracic Surgery Network and the National Institutes of944 The Journal of Thoracic and Cardiovascular SurgHealth–sponsored study. It is an important study because the ques-
tion is important for choosing who should receive AF and who
should receive extra care. If you just do the aortic valve, should
you open the left atrium for a fullMaze procedure or offer a limited
procedure with a lower success rate and perceived lower risk? On
the basis of my latest experience, my personal approach is that the
sicker the patient, the more beneficial it is to add the Maze proce-
dure because you can restore AV synchrony, evenwith pacing, dur-
ing the perioperative period. We do not deal with high ventricular
response rate, arrhythmias, and such. It is easier to manage those
patients. Yes, you do extend surgery specifically for CABG and
AVR, but only 30 to 45 minutes, which is insignificant with the
kind of myocardial preservation we have today. This article is
showing that together with the long-term benefit, it should offer
better outcome to patients with aortic and coronary artery disease.
With the cardiopulmonary bypass management, we have to deal
with cardioplegia. I think adding 30 to 45 minutes of bypass
time is not as big a deal as it was 10 years ago.
Dr John Chen (Honolulu, Hawaii). Are you treating this group
of patients, the AVR group, the same as your mitral valve group
with AF in your practice?
Dr Ad. Unless they have new-onset AF and a left atrium less
than 3.5 cm, which for the subgroup of patients who are not in-
cluded in this article, we perform a full Maze procedure in all of
them, yes. For those with new-onset AF and a small left atrium,
we are performing only pulmonary vein isolation and AVR or
CABG.ery c April 2012
